Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03536065 Recruiting - Prostate Cancer Clinical Trials

Post-Discharge Opioid Reduction Intervention for Open, Laparoscopic, and Endoscopic Surgery

ORIOLES
Start date: August 1, 2017
Phase: Phase 4
Study type: Interventional

ORIOLES is a pre-post study designed to improve quality of opioid prescribing and use after discharge for patients undergoing urologic surgery. The study will initially focus on a pre-defined cohort of patients undergoing radical prostatectomy. After the predefined study period and results are obtained, the intervention may be applied to all urologic surgeries based on the degree of improvement demonstrated by the study.

NCT ID: NCT03526510 Recruiting - Prostate Cancer Clinical Trials

Hypofractionated Boost vs Conventionally Fractionated Boost for Localized High Risk Prostate Cancer

Start date: June 2011
Phase: N/A
Study type: Interventional

Randomized trial comparing 2 external beam radiotherapy fractionation schemes in patients with localized high risk prostate cancer. Primary endpoint is acute toxicity.

NCT ID: NCT03525652 Recruiting - Prostate Cancer Clinical Trials

Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer Treatment

Start date: February 22, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study is to evaluate the safety and efficacy of a therapeutic vaccine in combination with PD-1 knockout T cells in the treatment of advanced prostate cancer.

NCT ID: NCT03516110 Recruiting - Prostate Cancer Clinical Trials

Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy

PRISME
Start date: March 9, 2018
Phase:
Study type: Observational [Patient Registry]

The objective of the study is to compare the evolution over 6 months of Health-Related Quality of Life (HRQOL) among different age groups in subjects with prostate cancer treated with GnRH agonist therapy.

NCT ID: NCT03516045 Recruiting - Prostate Cancer Clinical Trials

A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer

Start date: April 23, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is to investigate the clinical value of [18F]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-neurotensin(18F-AlF-NOTA-neurotensin)positron emission tomography / computed tomography (PET/CT) in patients with prostate cancer (PCa).

NCT ID: NCT03511664 Recruiting - Prostate Cancer Clinical Trials

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

VISION
Start date: May 23, 2018
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-PSMA-617 in addition to best supportive/best standard of care versus patients treated with best supportive/best standard of care alone. Key secondary objectives are an arm-to-arm comparison of the following: - Radiographic progression-free survival (rPFS) - Response Evaluation Criteria in Solid Tumors (RECIST) response - Time to a first symptomatic skeletal event (SSE) Additional Secondary Objectives: - Safety and tolerability of 177Lu-PSMA-617 - Health-related quality of life (HRQoL; EQ-5D-5L, FACT-P and Brief Pain Inventory - Short Form (BPI-SF)) - Health economics - Progression-free survival (PFS) (radiographic, clinical, or prostate-specific antigen [PSA] progression-free survival) - Biochemical response as measured by PSA. Alkaline phosphatase [ALP] levels and lactate dehydrogenase [LDH] levels will also be measured.

NCT ID: NCT03511196 Recruiting - Prostate Cancer Clinical Trials

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

Start date: May 17, 2018
Phase: Early Phase 1
Study type: Interventional

Adaptive Androgen Deprivation Therapy (ADT) plus Standard of Care. The purpose of this study is to develop adaptive therapy for high risk metastatic castration sensitive prostate cancer (mCSPC).

NCT ID: NCT03508011 Recruiting - Breast Cancer Clinical Trials

A Study of IMP4297 in Patients With Advanced Solid Tumors

Start date: August 23, 2017
Phase: Phase 1
Study type: Interventional

This is a Phase I, first-in-human, open-label, dose-escalation study of IMP4297 administered orally once every day to patients with advanced solid tumors for whom standard therapy either does not exist or has proven to be ineffective or intolerable. Patients with advanced breast cancer, ovarian cancer or prostate cancer are preferred. There are two stages to this study: a dose-escalation stage and a dose-expansion stage.

NCT ID: NCT03507725 Recruiting - Prostate Cancer Clinical Trials

Early Staged Consent Before Prostate Biopsy

Start date: April 11, 2018
Phase: N/A
Study type: Interventional

There is a fundamental need for novel study designs that can improve patient understanding during informed consent, encourage This is a pilot study and a novel approach to clinical trials, testing the feasibility and acceptability of two-stage consent in the context of a trial integrated into routine clinical practice. The investigator will use, as a model, a trial of a brief mind-body intervention) with guided imagery for procedural pain at the time of prostate biopsy. In the design, patients will first be approach for consent to 1) have their routinely collected clinical data used for research purposes and 2) be randomly selected to be offered an intervention to improve the experience of prostate biopsy. Only patients randomized to the experimental arm will be informed about the benefits and harms of the intervention and will sign a second consent for the experimental treatment.

NCT ID: NCT03507543 Recruiting - Breast Cancer Clinical Trials

The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors

Start date: February 3, 2017
Phase: Phase 1
Study type: Interventional

This is a phase 1, First-In-Human, open label study, trialing a new PARP (poly-ADP ribose polymerase) inhibitor medication IMP4297 in participants with advanced solid tumour.